Navigation Links
Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
Date:6/6/2009

the FDA may not agree with Orexigen's interpretation of efficacy and safety results; earlier clinical trials may not be predictive of future results; Contrave or Empatic may not receive regulatory approval on a timely basis or at all, and the FDA may require Orexigen to complete additional clinical, non-clinical or other requirements prior to the submission or the approval of NDAs for either product candidate; the potential for adverse safety findings relating to Contrave or Empatic to delay or prevent regulatory approval or commercialization, or result in product liability claims; the third parties on whom Orexigen relies to assist with the development programs for Contrave or Empatic, including clinical investigators, contract laboratories, clinical research organizations and manufacturing organizations, may not successfully carry out their contractual duties or obligations or meet expected deadlines, and the quality or accuracy of the data or materials generated by such third parties may be of insufficient quality to include in the Company's regulatory submissions; the ability of Orexigen and its licensors to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
2. Orexigen(R) Therapeutics to Present at Upcoming Meetings
3. Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
4. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
5. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
6. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
7. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
8. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
9. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
10. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
11. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... More than 5 million Americans are currently living ... will die with Alzheimer’s or another dementia, according to ... many Americans into looking for ways to improve their ... cognitive disorders. Jonathan Weisman, president of Biohack Pure, is ...
(Date:1/15/2014)... January 15, 2014 The Microcompetition with Foreign ... disease. One of these latent viruses is the Epstein Barr ... (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that ... study found that RA patients have high concentrations of EBV ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... the rising trend toward miniaturization, carbon nanotubes which ... and possess several unique and very useful properties ... blocks in nanosized electronic and mechanical devices. But it ... tendency to clump together, that make it difficult for ...
... testament to tight integration and ... excellent ... ), a,leader in radiology and medical image and information management solutions,today ... than 100 facilities that use MEDITECH(TM) as their health,information system. AMICAS ...
... device industry to benefit ... trial recruitment efforts, MINNEAPOLIS, May 27 ... has strengthened the,pharmaceutical side of its business with ... a commitment to leveraging differentiators unique,to the medical ...
Cached Biology Technology:Weizmann Institute scientists create new nanotube structures 2AMICAS Announces Integrations at More Than 100 MEDITECH Facilities 2AMICAS Announces Integrations at More Than 100 MEDITECH Facilities 3ThreeWire Expands Presence in the Pharmaceutical Arena 2
(Date:4/24/2014)... --- New research shows that cells are more resilient ... thought. Even when missing critical components, cells can adapt ... way. , In a study published in this week,s ... Michigan State University showed that cells can grow normally ... , "Our genetic information is stored in DNA, which ...
(Date:4/24/2014)... is very pleased to announce that it has assumed ... from the University of Wisconsin. , The ... open-access, peer-reviewed journal that publishes papers on all aspects ... from the molecular to the ecological -- as well ... available to individuals and institutions, and it provides a ...
(Date:4/24/2014)... be improved with new insights into the make-up of ... the Amazon Basin have revealed unprecedented detail of the ... by comparing satellite maps with hundreds of field plots. ... more accurately the amount of carbon each tree can ... schemes, in which trees are given a cash value ...
Breaking Biology News(10 mins):Cell resiliency surprises scientists 2ESA to publish the Journal of Insect Science 2Amazon rainforest survey could improve carbon offset schemes 2
... National Institute of General Medical Sciences, part of the ... Models of Infectious Disease Agent Study for a research ... led by Stephen Eubank, professor. Infectious diseases pose ... worldwide. The Models of Infectious Disease Agent Study (MIDAS) ...
... There might be a time when instead of just drinking ... skin as a way of preventing harmful sun damage or ... caffeine guards against certain skin cancers at the molecular level ... ATR. Scientists believe that based on what they have learned ...
... from NYU Langone Medical Center,s Departments of Orthopaedic Surgery ... used to detect subtle changes in joint cartilage microstructure ... key markers of early osteoarthritis (OA). By using these ... can shift the management of the disease from eventual ...
Cached Biology News:National Institutes of Health renews successful infectious disease research study 2National Institutes of Health renews successful infectious disease research study 3More evidence that caffeine lowers risk of skin cancer 2NYU Langone experts find MRI techniques can detect early osteoarthritis 2
...
... have moderate chemiluminescence efficiencies and the chemistry ... have the added benefit that they require ... the background signal. This benefit has been ... immunoassay applications. These compounds can also be ...
ssDNA from PCR DNA in less than 1 hour. No gels, columns, or slurries. Sequence from high quality ssDNA: clearer reads, longer runs....
Applications: Immunohistochemistry, ISH, FISH, CISH....
Biology Products: